MCID: NLS001
MIFTS: 47

Nelson Syndrome malady

Categories: Rare diseases, Endocrine diseases, Skin diseases

Aliases & Classifications for Nelson Syndrome

Aliases & Descriptions for Nelson Syndrome:

Name: Nelson Syndrome 12 50 56 52 42 14 69
Ridges-off-the-End Syndrome 50
Nelson's Syndrome 12
Dermal Ridges 50

Classifications:

Orphanet: 56  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:4968
ICD10 33 E24.1
MeSH 42 D009347
NCIt 47 C84917
SNOMED-CT 64 190503006 43019009
Orphanet 56 ORPHA199244
MESH via Orphanet 43 D009347
ICD10 via Orphanet 34 E24.1
UMLS via Orphanet 70 C0027577
UMLS 69 C0027577

Summaries for Nelson Syndrome

MalaCards based summary : Nelson Syndrome, also known as ridges-off-the-end syndrome, is related to hand and foot deformity with flat facies and dubin-johnson syndrome, and has symptoms including lower limb muscle weakness, hypertension and increased intracranial pressure. An important gene associated with Nelson Syndrome is SST (Somatostatin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Corticotropin-releasing hormone signaling pathway. The drugs Darunavir and Ritonavir have been mentioned in the context of this disorder. Affiliated tissues include pituitary and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Nelson Syndrome

Diseases related to Nelson Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
id Related Disease Score Top Affiliating Genes
1 hand and foot deformity with flat facies 10.9
2 dubin-johnson syndrome 10.8
3 cerebral hemisphere lipoma 10.2 PRL SST
4 lung occult small cell carcinoma 10.2 PRL SST
5 pituitary adenoma, acth-secreting 10.2 PRL SST
6 burning mouth syndrome type 3 10.1 POMC SST
7 renal hypoplasia, bilateral 10.1 POMC SST
8 water-clear cell adenoma 10.1 POMC SST
9 vaginal adenoma 10.1 POMC SST
10 mitochondrial complex ii deficiency 10.1 POMC SST
11 axial osteomalacia 10.1 PRL SST
12 hypoaldosteronism, congenital, due to cmo i deficiency 10.1 NR3C1 POMC
13 eccrine papillary adenocarcinoma 10.1 POMC SST
14 congenital tricuspid stenosis 10.1 POMC PRL
15 vertebral artery occlusion 10.1 POMC PRL
16 wheat allergy 10.1 POMC PRL
17 pancreatic colloid cystadenoma 10.1 POMC PRL
18 cataract 21, multiple types 10.1 NR3C1 POMC
19 non-syndromic x-linked intellectual disability 10.1 POMC SST
20 olfactory nerve neoplasm 10.1 POMC PRL
21 caudal regression syndrome 10.1 POMC PRL
22 kindler syndrome 10.1 POMC PRL
23 bone benign neoplasm 10.1 POMC PRL
24 acute laryngitis 10.1 POMC PRL
25 neurogenic arthropathy 10.1 POMC SST
26 sphingolipidosis 10.0 POMC PRL
27 peeling skin syndrome 10.0 NR3C1 POMC
28 capillary disease 10.0 POMC PRL
29 lymph node cancer 10.0 CRH NR3C1
30 diencephalic neoplasm 10.0 POMC PRL
31 bone dysplasia azouz type 10.0 CRH SST
32 mucopolysaccharidosis type vi 10.0 POMC PRL
33 chondroma 10.0 POMC SST
34 hemoglobin c disease 10.0 CRH PRL
35 transmitted_by 10.0 POMC PRL
36 hypoglycemic coma 10.0 CRH NR3C1
37 pelvic muscle wasting 10.0 POMC PRL
38 chronic eosinophilic pneumonia 10.0 CRH PRL
39 hypogonadism cardiomyopathy 10.0 CRH POMC
40 femur bifid with monodactylous ectrodactyly 10.0 CRH POMC
41 african histoplasmosis 9.9 POMC PRL SST
42 extragonadal nonseminomatous germ cell tumor 9.9 POMC PRL SST
43 malignant otitis externa 9.9 CRH POMC
44 protein s deficiency 9.9 POMC PRL SST
45 pulmonary neuroendocrine tumor 9.9 POMC PRL SST
46 rheumatic encephalitis 9.9 POMC PRL SST
47 autoimmune disease of endocrine system 9.9 CRH POMC
48 aflatoxins-related hepatocellular carcinoma 9.9 POMC PRL
49 bile acid synthesis defect, congenital, 4 9.9 POMC PRL SST
50 cold-induced sweating syndrome 2 9.9 POMC PRL SST

Graphical network of the top 20 diseases related to Nelson Syndrome:



Diseases related to Nelson Syndrome

Symptoms & Phenotypes for Nelson Syndrome

Human phenotypes related to Nelson Syndrome:

56 32 (show all 27)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lower limb muscle weakness 56 32 Frequent (79-30%) HP:0007340
2 hypertension 56 32 Frequent (79-30%) HP:0000822
3 increased intracranial pressure 56 32 Occasional (29-5%) HP:0002516
4 type ii diabetes mellitus 56 32 Frequent (79-30%) HP:0005978
5 visual impairment 56 32 Frequent (79-30%) HP:0000505
6 hypokalemia 56 32 Frequent (79-30%) HP:0002900
7 anterior hypopituitarism 56 32 Occasional (29-5%) HP:0000830
8 diabetes insipidus 56 32 Very rare (<4-1%) HP:0000873
9 striae distensae 56 32 Frequent (79-30%) HP:0001065
10 pituitary corticotropic cell adenoma 56 32 Very frequent (99-80%) HP:0008291
11 increased urinary cortisol level 56 32 Very frequent (99-80%) HP:0012030
12 intracranial hemorrhage 56 32 Very rare (<4-1%) HP:0002170
13 slow decrease in visual acuity 56 32 Frequent (79-30%) HP:0007924
14 generalized hyperpigmentation 56 32 Frequent (79-30%) HP:0007440
15 testicular neoplasm 56 32 Very rare (<4-1%) HP:0010788
16 adrenocorticotropic hormone excess 56 32 Obligate (100%) HP:0011749
17 secondary hypercorticolism 56 32 Obligate (100%) HP:0011744
18 bitemporal hemianopia 56 32 Frequent (79-30%) HP:0030521
19 abnormal kinetic perimetry test 56 32 Frequent (79-30%) HP:0030591
20 optic nerve compression 56 32 Occasional (29-5%) HP:0007807
21 quadriceps muscle atrophy 56 32 Occasional (29-5%) HP:0009050
22 oculomotor nerve palsy 56 32 Occasional (29-5%) HP:0012246
23 prolactin excess 56 32 Very rare (<4-1%) HP:0000870
24 pituitary carcinoma 56 32 Very rare (<4-1%) HP:0011763
25 ocular pain 56 32 Very rare (<4-1%) HP:0200026
26 abnormality of the sphenoid sinus 56 32 Very rare (<4-1%) HP:0430022
27 increased circulating cortisol level 56 Very frequent (99-80%)

MGI Mouse Phenotypes related to Nelson Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 CRH NR3C1 POMC PPARG PRL SST
2 homeostasis/metabolism MP:0005376 9.88 CRH NR3C1 POMC PPARG PRL SST
3 immune system MP:0005387 9.85 CRH NR3C1 POMC PPARG PRL SST
4 endocrine/exocrine gland MP:0005379 9.83 CRH NR3C1 POMC PPARG PRL
5 adipose tissue MP:0005375 9.78 CRH NR3C1 POMC PPARG
6 integument MP:0010771 9.72 NR3C1 POMC PPARG PRL CRH
7 liver/biliary system MP:0005370 9.65 NR3C1 POMC PPARG PRL CRH
8 nervous system MP:0003631 9.63 CRH NR3C1 POMC PPARG PRL SST
9 no phenotypic analysis MP:0003012 9.35 CRH NR3C1 POMC PPARG SST
10 renal/urinary system MP:0005367 8.92 CRH NR3C1 POMC PPARG

Drugs & Therapeutics for Nelson Syndrome

Drugs for Nelson Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
2
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3 155213-67-5 392622
3
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
4
Everolimus Approved Phase 4 159351-69-6 6442177
5
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
7
Clopidogrel Approved, Nutraceutical Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
8 Anti-HIV Agents Phase 4,Phase 3,Phase 2
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
13 Neurotransmitter Agents Phase 4,Phase 3
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
15 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
16 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
17
protease inhibitors Phase 4,Phase 3,Phase 2
18 Albumin-Bound Paclitaxel Phase 4
19 Analgesics Phase 4,Phase 3
20 Analgesics, Non-Narcotic Phase 4,Phase 3
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
23 Antipyretics Phase 4,Phase 3
24 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
25 Cyclooxygenase Inhibitors Phase 4,Phase 3
26 Fibrinolytic Agents Phase 4,Phase 3
27 Platelet Aggregation Inhibitors Phase 4,Phase 3
28 Prasugrel hydrochloride Phase 4,Phase 3 389574-19-0
29 Purinergic P2 Receptor Antagonists Phase 4,Phase 3
30 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3
31
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
32
Didanosine Approved Phase 3 69655-05-6 50599
33
Efavirenz Approved, Investigational Phase 3,Phase 2 154598-52-4 64139
34
Emtricitabine Approved, Investigational Phase 3 143491-57-0 60877
35
Stavudine Approved, Investigational Phase 3 3056-17-5 18283
36
Ticlopidine Approved Phase 3 55142-85-3 5472
37
Rivaroxaban Approved Phase 3 366789-02-8
38
Eptifibatide Approved, Investigational Phase 3 188627-80-7 123610
39
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
40
Exenatide Approved, Investigational Phase 3 141758-74-9 15991534
41
Tipranavir Approved, Investigational Phase 2, Phase 3 174484-41-4 65027
42
Tenofovir Approved, Investigational Phase 3 147127-20-6 464205
43
Pregabalin Approved, Illicit, Investigational Phase 3 148553-50-8 5486971
44
Clarithromycin Approved Phase 3 81103-11-9 84029
45
Ethambutol Approved Phase 3,Phase 2 74-55-5 3279 14052
46
Rifabutin Approved Phase 3,Phase 2 72559-06-9 6323490
47
Lamivudine Approved, Investigational Phase 3,Phase 2 134678-17-4 60825
48
Nevirapine Approved Phase 3,Phase 2 129618-40-2 4463
49
Zalcitabine Approved Phase 3 7481-89-2 24066
50
Zidovudine Approved Phase 3,Phase 2 30516-87-1 35370

Interventional clinical trials:

(show top 50) (show all 76)
id Name Status NCT ID Phase
1 Double Protease Inhibitor to Darunavir Switch Study Completed NCT00531557 Phase 4
2 The Dual Antiplatelet Therapy Study (DAPT Study) Completed NCT00977938 Phase 4
3 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
4 A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females Unknown status NCT00547469 Phase 2, Phase 3
5 A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs Unknown status NCT00006208 Phase 3
6 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Completed NCT00699998 Phase 3
7 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome Completed NCT00658515 Phase 3
8 An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome Completed NCT00809965 Phase 3
9 A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus Completed NCT01042769 Phase 3
10 Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy Completed NCT01076764 Phase 3
11 Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Completed NCT01144338 Phase 3
12 Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects Completed NCT00146328 Phase 2, Phase 3
13 Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection Completed NCT00002441 Phase 3
14 Atripla to Raltegravir Switch Study for CNS Toxicity Completed NCT01195467 Phase 3
15 Treatment of Pain Associated With Fibromyalgia Completed NCT02187159 Phase 3
16 A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo Completed NCT00002101 Phase 3
17 Reducing HIV: Safer Sex Skill Building in Pregnant Drug Abusing Women Completed NCT00619320 Phase 2, Phase 3
18 The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs Completed NCT00002368 Phase 3
19 Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding Completed NCT00074412 Phase 3
20 Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy Completed NCT00002109 Phase 3
21 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS Recruiting NCT02525939 Phase 3
22 Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® Recruiting NCT01908192 Phase 2, Phase 3
23 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Recruiting NCT02344290 Phase 3
24 Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa Recruiting NCT02968849 Phase 2, Phase 3
25 ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab Active, not recruiting NCT01663402 Phase 3
26 An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia Active, not recruiting NCT02234583 Phase 3
27 A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardi Active, not recruiting NCT01492361 Phase 3
28 Phase III Acute Coronary Syndrome Terminated NCT00831441 Phase 3
29 Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV Terminated NCT00080119 Phase 2, Phase 3
30 Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Completed NCT02084563 Phase 2
31 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals Completed NCT00885703 Phase 1, Phase 2
32 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2
33 BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women Completed NCT00074425 Phase 2
34 Safety and Efficacy of Zinc Supplementation in HIV-1-Infected Children in South Africa Completed NCT00138047 Phase 2
35 Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals Completed NCT00034866 Phase 2
36 Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs Completed NCT00004852 Phase 2
37 The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease Completed NCT00002324 Phase 2
38 Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV Completed NCT00307151 Phase 2
39 MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Recruiting NCT02171104 Phase 2
40 Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia Recruiting NCT00630253 Phase 1, Phase 2
41 Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia Recruiting NCT01464164 Phase 1, Phase 2
42 Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults Recruiting NCT02915016 Phase 1, Phase 2
43 Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients Recruiting NCT02741323 Phase 2
44 Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV Active, not recruiting NCT01601626 Phase 2
45 StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Not yet recruiting NCT02765997 Phase 2
46 Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®-or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants Not yet recruiting NCT03122223 Phase 1, Phase 2
47 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2
48 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2
49 A Study of BufferGel in Women Completed NCT00000927 Phase 1
50 A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea Completed NCT00000980 Phase 1

Search NIH Clinical Center for Nelson Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: nelson syndrome

Genetic Tests for Nelson Syndrome

Anatomical Context for Nelson Syndrome

MalaCards organs/tissues related to Nelson Syndrome:

39
Pituitary, Testes

Publications for Nelson Syndrome

Articles related to Nelson Syndrome:

(show all 17)
id Title Authors Year
1
Nelson Syndrome: Update on Therapeutic Approaches. ( 25683128 )
2015
2
Nelson syndrome: definition and management. ( 25248597 )
2014
3
Positron emission tomography-computed tomography coregistration for diagnosis and intraoperative localization in recurrent nelson syndrome. ( 23943718 )
2013
4
Hormonal Secretion and Quality Of Life in Nelson Syndrome and Cushing Disease After Long Acting Repeatable Octreotide: A Short Series and Update. ( 22820717 )
2012
5
Localization of remnant and ectopic adrenal tissues with cosyntropin-stimulated 18F-FDG-PET/CT in a patient with Nelson syndrome with persistent hypercortisolism. ( 21131539 )
2010
6
Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome. ( 21061089 )
2010
7
Gamma knife stereotactic radiosurgery of Nelson syndrome. ( 18996962 )
2009
8
Visual vignette. Nelson syndrome. ( 18753114 )
2008
9
Nelson syndrome: comprehensive review of pathophysiology, diagnosis, and management. ( 17961028 )
2007
10
Nelson syndrome: historical perspectives and current concepts. ( 17961024 )
2007
11
Regulation of body weight by proopiomelanocortin peptides in humans: lessons from the Nelson syndrome. ( 16061931 )
2005
12
Excessive testosterone production in a patient with Nelson syndrome and bilateral testicular tumors. ( 8860745 )
1996
13
Therapy for acromegaly, Cushing disease and Nelson syndrome. ( 7415173 )
1980
14
Treatment of acromegaly, Cushing disease and Nelson syndrome. ( 7415170 )
1980
15
Human adenohypophysis in Nelson syndrome. Ultrastructural and clinical study. ( 178289 )
1976
16
Cortisol secretion in Nelson syndrome: Persistence after "total" adrenalectomy for Cushing syndrome. ( 171463 )
1975
17
Dissociation of plasma and spinal fluid ACTH in Nelson syndrome. ( 4362182 )
1974

Variations for Nelson Syndrome

Expression for Nelson Syndrome

Search GEO for disease gene expression data for Nelson Syndrome.

Pathways for Nelson Syndrome

GO Terms for Nelson Syndrome

Cellular components related to Nelson Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.62 POMC PRL

Biological processes related to Nelson Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 9.48 CRH PRL
2 regulation of blood pressure GO:0008217 9.46 POMC PPARG
3 response to estrogen GO:0043627 9.43 CRH PPARG
4 steroid hormone mediated signaling pathway GO:0043401 9.4 NR3C1 PPARG
5 cellular response to dexamethasone stimulus GO:0071549 9.37 CRH NR3C1
6 response to nutrient GO:0007584 9.33 PPARG PRL SST
7 response to immobilization stress GO:0035902 9.32 CRH PPARG
8 parturition GO:0007567 9.26 CRH PRL
9 response to drug GO:0042493 9.26 CRH PPARG PRL SST
10 hormone-mediated apoptotic signaling pathway GO:0008628 8.62 CRH SST

Molecular functions related to Nelson Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 8.96 NR3C1 PPARG
2 hormone activity GO:0005179 8.92 CRH POMC PRL SST

Sources for Nelson Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....